titer – Page 10 – Communicable Diseases Research

Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers

의료 종사자들 사이에서 ChAdOx1 nCoV-19 백신의 첫 번째 접종 전후의 5가지 SARS-CoV-2 항체 분석 결과 비교

Immunoassays

Published on 2021-06-302022-09-12
Journal: Journal of Clinical Microbiology [Category] MERS, SARS, 진단,

Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination

Article

Published on 2021-06-252022-10-28
Journal: Vaccines [Category] COVID-19,

[키워드] anti-N IgG Anti-RBD IgG anti-S IgG AstraZeneca avidity B.1.1.7 B.1.351 BNT162b2 ChAdOx1 concern contribute convalescent COVID-19 cVNT demonstrated detectable development domain Evidence examined humoral immune response Humoral immunity IgG immune response immunoblot Immunoglobulin increase in Infection Maturity Moderna mRNA-1273 neutralization Pfizer/BioNTech RBD reactivity robust SARS-CoV-2 SARS-COV-2 infection second dose sera Specific starting sVNT tested titer vaccination vaccine dose vaccinee vaccinees variants of concern viral spike virus variants virus-neutralizing antibodies virus-neutralizing antibody VoC was determined were used
[DOI] 10.3390/vaccines9070700 PMC 바로가기 [Article Type] Article

Evaluation of SARS-CoV-2 Spike Protein Antibody Titers in Cord Blood after COVID-19 Vaccination during Pregnancy in Polish Healthcare Workers: Preliminary Results

Communication

Published on 2021-06-192022-10-28
Journal: Vaccines [Category] COVID-19,

[키워드] acute respiratory syndrome Administered analyzed Antenatal anti-S antibodies antibody Antibody titers antibody transfer BNT162b2 mRNA complementary CORD coronavirus coronavirus disease correlated COVID-19 COVID-19 vaccination COVID-19 vaccine determine develop Efficacy enrolled evaluate Evidence first dose gestation IgG antibody IgG antibody titer immunization increased risk initial lack Mortality Neonatal pandemic Patient positive correlation Pregnancy pregnant women prevalence of COVID-19 Protein Result S protein SARS-CoV-2 second dose serum severe COVID-19 spike the vaccine titer transfer umbilical umbilical cord blood vaccination vaccination against COVID-19 Vaccine
[DOI] 10.3390/vaccines9060675 PMC 바로가기 [Article Type] Communication

Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart

Article

Published on 2021-06-152022-10-28
Journal: Vaccines [Category] COVID-19,

[키워드] Administered Adverse adverse effect adverse effects Anti-RBD antibody anti-SARS-CoV-2 Antibody titer BNT162b2 BNT162b2 vaccine Clinical characteristics collected COVID-19 COVID-19 diagnosis dose Effect Factor HCWs Health surveillance healthcare worker Healthcare workers home IgG immune response immunization involved Italian Italy knowledge Neutralizing Nursing operator performed Protective protocol provided questionnaire Sample SARS-CoV-2 second dose serological severe adverse effect significantly higher socio-demographic subject subunit the spike protein the vaccine titer vaccination Vaccines was determined Week
[DOI] 10.3390/vaccines9060652 PMC 바로가기 [Article Type] Article

IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

Research Article

Published on 2021-06-022022-10-30
Journal: mSphere [Category] COVID-19,

[키워드] antibody Antibody titer Antibody titers approved Blood booster calculated can be used caused Cell clinical clinical samples clinical specificity Clinical use clinical validation Concentration correlated country COVID-19 COVID-19 vaccines Critical death determinant development disease displaying dosing schedule elicit feasibility FIVE future infection gold standard high-throughput assay human serum Infection infections limit limit of detection measure monoclonal antibody Neutralizing antibodies neutralizing antibody Neutralizing antibody response Neutralizing antibody titer parameter performed plaque-reduction neutralization test plasma Precision Prevent protective immune response question required SARS-CoV-2 SARS-CoV-2 immunity SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 spike glycoprotein SARS-CoV-2-neutralizing antibodies SARS-CoV-2-neutralizing antibody sensitivity standard curve strong immune response surrogate virus titer turn utility vaccinated individual vaccinated individuals vaccination Vaccine Vaccine-induced immunity validation vesicular stomatitis virus virus virus assay widespread
[DOI] 10.1128/mSphere.00170-21 PMC 바로가기 [Article Type] Research Article

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

회복기 혈청 및 백신 유도 항체는 글로벌 SARS-CoV-2 변이체 스파이크에 대한 중화 역가를 크게 유지합니다

Research Article

Published on 2021-06-012022-09-10
Journal: mBio [Category] MERS, SARS, 변종, 진단,

[키워드] 20A.EU2 a minor acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody B.1.1.248 B.1.1.7 B.1.351 BNT162b2 Cluster cocktail COH.20G/677H coronavirus decrease E484K effective elicited less maintain mink cluster 5 minor monoclonal antibody monoclonal antibody therapy Mutation natural infection neutralization neutralize neutralized Neutralizing activity Patient Pfizer Pfizer BNT162b2 Prevalence Pseudotyped virus Pseudotyped viruses raise Regeneron REGN10933 REGN10987 respiratory SARS-CoV-2 sera severe acute respiratory syndrome Coronavirus spike Spike protein Spike proteins therapeutic therapy titer vaccination Vaccine variant variants viruses
[DOI] 10.1128/mBio.00696-21 PMC 바로가기 [Article Type] Research Article

Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit receptor binding and viral replication

Research Article

Published on 2021-05-282022-10-28
Journal: PLoS ONE [Category] COVID-19, SARS,

[키워드] ACE2 acute respiratory syndrome Angiotensin converting enzyme-2 animal model antibody applied binding binding interactions binding site carried caused Concentration coronavirus COVID-19 Critical Culture effective evaluated feasibility feasible global pandemic glycoprotein human Ace2 protein immunized Immunoglobulin in vitro Infection Infectious disease inhibit inhibited inhibiting initial intranasal intranasally mitigate mucosal pandemic peak concentration peaking produced Prophylaxis PROTECT Protective Protein raised receptor Receptor binding reducing replication of SARS-CoV-2 respiratory pathogen Result resulting SARS-CoV-2 shown significantly specificity spike glycoprotein spread of COVID-19 the SARS-CoV-2 virus titer Vaccine Vero Cell viral replication viral spike virulence virus
[DOI] 10.1371/journal.pone.0252399 PMC 바로가기 [Article Type] Research Article

Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial

건강한 지원자와 COVID-19 환자에 대한 메플라주맙의 안전성 및 효능: 무작위 1상 및 탐색적 2상 시험

Clinical Trial

Published on 2021-05-172022-08-13
Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, SARS, 비임상, 임상, 진단, 치료제,

[키워드] abstracts accelerate acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-CD147 antibody assigned biodistribution study blocking C max cardiac blood–pool ratio CD147 Cohort cohorts conducted control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients COVID-19 pneumonia determine discharged dosage double-blinded Efficacy eight enrolled evaluate Evidence exploratory phase 2 exploratory phase 2 study healthy subjects healthy volunteer healthy volunteers hospitalized patient humanized IgG in vitro incidence indicated Infection involved lung lung tissue Meplazumab meplazumab treatment monoclonal antibody Patient patients Peripheral blood pharmacokinetic characteristics pharmacokinetics Phase 1 phase 1 study phase 1 trial Phase 2 Placebo placebo-controlled Pneumonia positive Prevent Randomized reached recent receptor reduced respiratory Safety safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication serum severe acute respiratory syndrome Coronavirus severity significantly subject suppress TEAE titer Tolerability Tolerance treatment-emergent adverse event Trial virus
[DOI] 10.1038/s41392-021-00603-6 PMC 바로가기 [Article Type] Clinical Trial

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Ad26.COV2.S 코비드-19 백신의 1-2a상 시험 중간 결과

Clinical Trial

Published on 2021-05-132022-09-11
Journal: The New England Journal of Medicine [Category] Fulltext, SARS, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus administration adverse event age All participants Antibody Response assigned authority candidate vaccine CD4+ T-cell CD8+ T-cell Cohort cohorts collected coronavirus coronavirus disease Coronavirus disease 2019 COV1001 COV2.S Department development dose Factor fatigue Fever full-length geometric mean geometric mean titer GMT headache healthy High dose Human increase in Infection Injection-site pain Interim Johnson & Johnson less low dose milliliter multicenter myalgia Neutralizing-antibody Neutralizing-antibody titers Older pandemic participant phase Placebo placebo-controlled primary end point profile provided Randomly reached reactogenicity receive regimen remained reported research and development respiratory response responses Result robust SARS-CoV-2 SARS-CoV-2 spike protein second dose serotype severe acute respiratory syndrome Coronavirus Spike protein Support systemic systemic adverse events T cells T-cell responses titer titers Trial two-dose regimen type 1 helper Vaccine vaccine candidate vaccine dose Viral viral particle wild-type virus
[DOI] 10.1056/NEJMoa2034201 PMC 바로가기 [Article Type] Clinical Trial

Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial

무작위 대조 시험에서 사용된 회복기 및 대조 혈장의 SARS-CoV-2에 대한 중화 활성

Randomized Controlled Trial

Published on 2021-05-012022-09-11
Journal: Transfusion [Category] MERS, SARS, 임상, 진단, 치료기술, 치료법, 치료제,

[키워드] 293 T cells 293T ACE2 Administered antibody Antibody titers approach binding calculated Cell convalescent convalescent plasma COVID-19 COVID-19 infection criteria detect Donor donors excluded exhibited FDA FFP transfusion Human immunodeficiency virus IgG antibody immunochromatographic test immunology immunology (other than RBC serology) individual Infection inhibited IQR median medium neutralization titer neutralize Neutralizing activity Neutralizing antibodies neutralizing antibody Neutralizing antibody titer neutralizing antibody titers non-specific nucleocapsid protein optical optical density plasma pseudovirus random Randomized controlled trial Randomized controlled trials Randomly randomly selected samples RBC RCT SARS-CoV-2 SARS-CoV-2 pseudovirus SARS2 screened selected serology Spike protein subset T cells tested titer Viral was collected
[DOI] 10.1111/trf.16283 PMC 바로가기 [Article Type] Randomized Controlled Trial